Argent Biopharma (AU:RGT) has released an update.
Argent BioPharma, a pioneering drug discovery company, has announced a collaboration with SINTEF to tackle chronic wound management using innovative nano-formulations. The company also revealed its plans to delist from the ASX and raised $2 million through a private placement at a substantial premium, indicating strong investor confidence in its growth potential.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.
